ArticleEC pharmacology and toxicology2019
Nanoneurotoxicity and Potential Nanotheranostics for Alzheimer's Disease.
Article in EC pharmacology and toxicology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 17 citations in OpenAlex.
- Alzheimer's Disease Pathology and Assistive Nanotheranostic Approaches for Its Therapeutic Interventions.International journal of molecular sciences · 2024Review
- Alzheimer's disease: from early pathogenesis to novel therapeutic approaches.Metabolic brain disease · 2024Review
- Intranasal Drug Delivery by Nanotechnology: Advances in and Challenges for Alzheimer's Disease Management.Pharmaceutics · 2023Review
- Metal Nanoparticles in Alzheimer's Disease.Journal of Alzheimer's disease reports · 2023Review
- Toxicologic Concerns with Current Medical Nanoparticles.International journal of molecular sciences · 2022Review
- Applications of Magnetic Particle Imaging in Biomedicine: Advancements and Prospects.Frontiers in physiology · 2022Review
- Repeated oral administration of low doses of silver in mice: tissue distribution and effects on central nervous system.Particle and fibre toxicology · 2021Article
- Exposure to CuO Nanoparticles Mediates NFκB Activation and Enhances Amyloid Precursor Protein Expression.Biomedicines · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Alzheimer's disease (AD) is the most common form of senile dementia and it is characterized by cognitive, motor and memory impairments. AD neuropathology includes toxic biomarkers, such as Aβ amyloid protein buildup between neurons disrupting connections, tau protein fibrillization and neuronal demise. These biomarkers are exacerbated with exposure to environmental borne or man-made nanoparticles or engineered nanomaterials (ENMs) as these nanoparticles are becoming more widely adopted for industrial applications. Studies suggest a link between nanoparticle exposure and neurotoxic responses, thus suggesting a contribution to AD pathology. This review summarizes research in the field of nanoparticles in terms of neurotoxic changes in the nervous system, as well as its relation to AD pathology. Studies involving silver, silica, copper oxide and iron oxide nanoparticles in mice suggest ranging neurotoxic reactions, such as disrupted neural connections, neuroinflammation, neuron cell death, redox stress, impairment of the blood-brain barrier (BBB), decrease in motor performance, demyelination of axons, decrease in long-term potentiation (LTP) and damage to DNA and brain structures. This review also examines beneficial effects of certain nanoparticles as potential therapeutic or diagnostic tools for AD.
Indexed as
Identifiers
31828253PMC6905634W3008695086What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.